4//SEC Filing
Aegerion Pharmaceuticals, Inc. 4
Accession 0001104659-16-159823
CIK 0001338042operating
Filed
Nov 29, 7:00 PM ET
Accepted
Nov 30, 7:48 PM ET
Size
18.4 KB
Accession
0001104659-16-159823
Insider Transaction Report
Form 4
GOTTO ANTONIO M JR MD D PHIL
Director
Transactions
- Disposition to Issuer
Common Stock
2016-11-29−13,916→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2016-11-29−9,988→ 0 totalExercise: $17.64From: 2014-06-01Exp: 2021-06-01→ Common Stock (9,988 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2016-11-29−12,854→ 0 totalExercise: $15.00From: 2015-06-05Exp: 2022-06-05→ Common Stock (12,854 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2016-11-29−14,700→ 0 totalExercise: $64.73From: 2014-06-26Exp: 2023-06-26→ Common Stock (14,700 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2016-11-29−18,000→ 0 totalExercise: $17.98From: 2016-06-26Exp: 2025-06-26→ Common Stock (18,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2016-11-29−10,238→ 0 totalExercise: $9.50From: 2013-10-27Exp: 2020-10-27→ Common Stock (10,238 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2016-11-29−5,012→ 0 totalExercise: $32.55From: 2015-06-26Exp: 2024-06-26→ Common Stock (5,012 underlying)
Footnotes (2)
- [F1]Disposed of in exchange for 14,272 common shares of Novelion Therapeutics Inc. pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective November 29, 2016. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc."
- [F2]Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor.
Documents
Issuer
Aegerion Pharmaceuticals, Inc.
CIK 0001338042
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001338042
Filing Metadata
- Form type
- 4
- Filed
- Nov 29, 7:00 PM ET
- Accepted
- Nov 30, 7:48 PM ET
- Size
- 18.4 KB